Targeted inhibition of AKT in pancreatic cancer

Current Cancer Therapy Reviews

Volumn 5, Issue 4, 2009, Pages 288-295

  Bowles, Tawnya L ^a   Parsons, Colin ^a   Muilenburg, Diego J ^a   Bold, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt; Apoptosis; Autophagy; NF B; Pancreatic cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 HYDROXYMETHYL CHIRO INOSITOL 2 O METHYL 3 O OCTADECYLCARBONATE; A 443654; AKT PROTEIN KINASE B SIGNALING INHIBITOR 2; CAMPTOTHECIN; CURCUMIN; DEOXYPHOSPHATIDYL MYO INOSITOL 1 (2 METHOXY 3 OCTADECYLOXYPROPYL HYDROGEN PHOSPHATE); DOXORUBICIN; GEMCITABINE; GENISTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL PHOSPHATE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NL 71 101; OLEANDRIN; PACLITAXEL; PERIFOSINE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG; VALYLGLUTAMYLLEUCYLASPARTYLPROLYLGLUTAMYLPHENYLALANYLGLUTAMYLPROLYLARGINYLALANYLARGINYLGLUTAMYLARGINYLTHREONYLTYROSYLALANYLPHENYLALANYLGLYCYLHISTIDINE; WORTMANNIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

EID: 71749088786     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339409789712654     Document Type: Review

References (92)

1. Heineman V. Present and future treatment of pancreatic cancer. Semin Oncol 2002; 29: 23-31. (Pubitemid 34753280)
2. Xiong HQ, Abbruzzese JL. Adjuvant therapy for pancreatic cancer: current status and future directions. Surg Oncol Clin N Am 2004; 13: 737-749 (Pubitemid 39209350)
3. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008; 8: 187-198 (Pubitemid 351688437)
4. Vivanco I, Sawyers C. The phophatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
5. Chang F, Lee J, Navolanic PM, et al. Involvement of the PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603. (Pubitemid 36395654)
6. Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci USA 2003; 100: 11712-11717
7. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
8. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-437 (Pubitemid 32751073)
9. Staal S, Hartley J. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med 1988; 167: 1259-1264 (Pubitemid 18111432)
10. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254: 274-277 (Pubitemid 21917339)
11. Nicholson K, Anderson N. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395 (Pubitemid 34214843)
12. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001; 15(17): 2203-2208 (Pubitemid 32843832)
13. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003; 17: 1352-1365
14. Garofalo RS, Orena SJ, Rafidi K, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 2003; 112: 197-208. (Pubitemid 38056356)
15. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 1998; 95: 14950-14955 (Pubitemid 29003737)
16. Vanhaesebroeck B, Alessi D. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346: 561-576 (Pubitemid 30171014)
17. Wick, MJ, Dong LQ, Riojas RA, Ramos FJ, Liu F. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1. J Biol Chem 2000; 275: 40400-40406 (Pubitemid 32064675)
18. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting it on the AKT. Cell 2002; 111: 293-303.
19. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95: 11211-11216 (Pubitemid 28450107)
20. Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999; 9(8): 393-404. (Pubitemid 29205782)
21. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000; 275(12): 8271-8274 (Pubitemid 30180163)
22. Hill M, Feng J, Hemmings BA. Identification of a plasma membrane raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 2002; 12: 1251-1255 (Pubitemid 34801175)
23. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitization in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003; 89: 391-397 (Pubitemid 36976331)
24. Luo Y, Smith RA, Guan R, et al. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 2004 43(5): 1254-1263 (Pubitemid 38176523)
25. Perugini RA, McDade TP, Jr, Vittimberga FJ, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-Kinase dependent. J Surg Res 2000; 90: 39-44.
26. Shah SA, Potter MW, Hedeshian MH, Kim RD, Chari RS, Callery MP. PI-3′ kinase and NF-kappaB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg 2001; 5: 603-612
27. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-3251 (Pubitemid 36712936)
28. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28: 353-358 (Pubitemid 38437337)
29. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001; 7: 3269-3275 (Pubitemid 32963853)
30. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-997
31. Su Z, Lebedeva IV, Gopalkrishnan RV, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001; 98: 10332-10337 (Pubitemid 32803020)
32. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003; 89: 391-397 (Pubitemid 36976331)
33. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65(19): 9064-9072
34. Yu S, Shen G, Khor TO, Kim JH, Kong AN. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008; 7(9): 2609-2620
35. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89(11): 2110-2115 (Pubitemid 38030911)
36. Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10(8): 2846-2850 (Pubitemid 38509164)
37. Samatar AA, Wang L, Mirza A, Koseoglu S, Liu S, Kumar CC. Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor. J Biol Chem 2002; 277(31): 28118-28126 (Pubitemid 34966764)
38. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23(53): 8571-8580 (Pubitemid 39576463)
39. Matsumoto J, Kaneda M, Tada M, et al. Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells. Jpn J Cancer Res 2002; 93(12): 1317-1326 (Pubitemid 36104871)
40. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3(11): 973-982 (Pubitemid 34428742)
41. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
42. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-10837 (Pubitemid 30751239)
43. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000; 67(3): 177-185
44. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. BCL-2 overexpression activates AKT and induces nuclear translocation in pancreatic cancer. J Cell Biochem 2007; 102(5): 1171-1179
45. Reuveni H, Livnah N, Geiger T, et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002; 41: 10304-10314 (Pubitemid 34856456)
46. Breitenlechner CB, Wegge T, Berillon L, et al. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J Med Chem 2004; 47: 1375-1390 (Pubitemid 38327465)
47. Obata T, Yaffe MB, Leparc GG, et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 2000; 275(46): 36108-36115 (Pubitemid 30841158)
48. Luo Y, Smith RA, Guan R, et al. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 2004; 43: 1254-1263 (Pubitemid 38176523)
49. Hiromura M, Okada F, Obata T, et al. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the protooncogene TCL1. J Biol Chem 2004; 279: 53407-53418 (Pubitemid 40051845)
50. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4(6): 977-986 (Pubitemid 40909080)
51. Li Q, Li T, Zhu GD, et al. Discovery of trans-3,4′- bispyridinylethylenes as potent and novel inhibitors of protein kinase B [PKB/Akt] for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett 2006; 16(6): 1679-1685 (Pubitemid 43197545)
52. Zhu GD, Gandhi VB, Gong J, et al. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg Med Chem Lett 2006; 16(13): 3424-3429 (Pubitemid 43777085)
53. Thomas SA, Li T, Woods KW, et al. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorg Med Chem Lett 2006; 16(14): 3740-3744 (Pubitemid 44137239)
54. Lindsley CW, Zhao Z, Leister WH, et al. Allosteric Akt [PKB] inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005; 15(3): 761-764 (Pubitemid 40143162)
55. Zhu GD, Gandhi VB, Gong J, et al. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J Med Chem 2007; 50(13): 2990-3003. (Pubitemid 47001242)
56. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxyphosphatidyl-myo-inositol analogues. Mol Cancer Ther 2003; 2: 389-399
57. Castillo SS, Brognard J, Petukhov PA, et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004; 64: 2782-2792 (Pubitemid 38500616)
58. Martelli AM, Tazzari PL, Tabellini G, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 17: 1794-1805 (Pubitemid 37185255)
59. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103
60. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005; 385: 399-408. (Pubitemid 40165072)
61. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64: 4394-4399 (Pubitemid 38856907)
62. Feun LG, Savaraj N, Bodey GP, et al. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 1984; 44: 3608-3612 (Pubitemid 14098619)
63. Feun LG, Blessing JA, Barrett RJ, Hanjani P. A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1993; 16: 506-508 (Pubitemid 2020378)
64. Wang YC, Kulp SK, Wang D, et al. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res 2008; 68(8): 2820-2830 (Pubitemid 351556281)
65. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006; 24(2): 306-314 (Pubitemid 46622059)
66. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs 2007; 18(8): 861-874
67. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Inhibition of AKT Abrogates Chemotherapy-Induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004; 198(4): 591-599 (Pubitemid 38446534)
68. Shi Y, Liu X, Han EK, et al. Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia 2005; 7(11): 992-1000.
69. Karin M. How NF-kappaB is activated: the role of the IkB kinase [IKK] complex. Oncogene 1999; 18(49): 6867-6874
70. Madrid LV, Mayo MW, Reuther JY, Baldwin AS, Jr. Akt stimulates the transactivation potential of the RelA/p65 subunit of NFkappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001; 276: 18934-18940 (Pubitemid 37411214)
71. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor [NF]-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998; 188: 211-216 (Pubitemid 28328620)
72. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-5799
73. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-5929
74. Benoit V, Hellin AC, Huygen S, Gielen J, Bours V, Merville MP. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter. Oncogene 2000; 19: 4787-4794 (Pubitemid 30814886)
75. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. NF-kappaB1 [p50] homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001; 276: 45380-45386
76. Basile JR, Eichten A, Zacny V, Münger K. NF-kappaB-mediated induction of p21[Cip1/Waf1] by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res 2003; 1: 262-270 (Pubitemid 36292611)
77. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003; 23: 8070-8083 (Pubitemid 37377499)
78. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 2003; 278: 51091-51099 (Pubitemid 38020344)
79. Xie K, Wei D, Huang S. Transcriptional anti-angiogenesis therapy of pancreatic cancer. Cytokine Growth Factor Rev 2006; 17: 147-156 (Pubitemid 43816895)
80. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999; 18: 6842-6844
81. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000; 20: 1626-1638
82. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470: M55-62.
83. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003; 22: 1365-1370 (Pubitemid 36384598)
84. Reed J. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behrin Inst Mtt 1996; 97: 72-100.
85. Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochim et Biophys Acta 2004; 1644: 229-249. (Pubitemid 38281277)
86. Høyer-Hansen M, Jäättelä M. Autophagy: an emerging target for cancer therapy. Autophagy 2008; 4(5): 574-580
87. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6(4): 304-312
88. Newman RA, Kondo Y, Yokoyama T, et al. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 2007; 6(4): 354-364 (Pubitemid 350136018)
89. Meuillet EJ, Ihle N, Baker AF, et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004; 14: 513-527
90. Thimmaiah KN, Easton JB, Germain GS, et al. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 2005; 280: 31924-31935
91. Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res 2005; 65: 2815-2824 (Pubitemid 40490084)
92. Mandal M, Kim S, Younes MN, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 2005; 92: 1899-1905 (Pubitemid 40826139)